Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development of $18.95M in Q2 FY2026
Q2 FY2026 research & development was $18.95M.
Context
- Research & development amounted to 4011.3% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 54.15M USD
- Year-over-year change
- +59.9%
- 1-year CAGR
- +59.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.15M | +59.9% |
| FY2024 | 2024-12-31 | 33.86M | — |
Research & Development vs competitors
How ATTO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +59.9% is the 3rd highest of 10, against a peer median of +46.0%.
- Research & development amounts to 4011.3% of revenue for ATTO, versus a peer median of 723.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M USD | -8.7% | +56.3% | 4685.4% |
| LTM Mar 2026 | $220.82M USD | +62.1% | +69.0% | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $153.74M USD | +46.0% | +182.5% | — |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $77M USD | — | — | 770.0% |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
| FY2025 | $54.15M USD | +59.9% | — | 4011.3% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M USD | +48.2% | +21.1% | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €39.31M EUR | +49.4% | — | — |
| FY2025 | $37.8M USD | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $15.25M USD | -66.4% | -18.8% | 28.4% | |
| Peer median (excluding ATTO) | — | +46.0% | +18.2% | 723.9% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 1.35M |
| Cost of Revenue | 313K | 804K |
| Gross Profit | (313K) | 546K |
| Gross Margin | — | 40.4% |
| Research & Development | 33.86M | 54.15M |
| Selling, General & Admin | 7.38M | 13.55M |
| Operating Expenses | 41.24M | 67.71M |
| Depreciation & Amortization | 313K | 804K |
| EBITDA | (41.24M) | (66.36M) |
| EBITDA Margin | — | -4915.2% |
| Operating Income | (41.55M) | (67.16M) |
| Operating Margin | — | -4974.7% |
| Interest Income | 3.44M | 6.63M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 1.75M | 6.53M |
| Income Before Tax | (39.8M) | (60.63M) |
| Pre-Tax Margin | — | -4490.9% |
| Income Tax Expense | 0 | 0 |
| Net Income | (39.8M) | (60.63M) |
| Net Margin | — | -4490.9% |
| EPS (Basic) | (1.05) | (1.42) |
| EPS (Diluted) | (1.05) | (1.42) |
| Weighted Avg Shares | 43.03M | 43.03M |
| Weighted Avg Shares (Diluted) | 43.03M | 43.03M |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.